Skip to main content

Legal Frameworks for Benefit Sharing: From Biodiversity to Human Genomics

  • Chapter
  • First Online:
Book cover Benefit Sharing

Abstract

The philosophical principle behind benefit sharing is simple. Those who contribute to scientific research ought to share in its benefits. This is a matter of justice. If benefit sharing does not take place, exploitation may have occurred. The term “benefit sharing” was popularized by the Convention on Biological Diversity (CBD), which was adopted at the Earth Summit in Rio in 1992. This chapter provides an overview of the key international instruments and guidelines that make provisions for benefit sharing. Legal instruments are often categorized as to whether they are binding or non-binding. With the exception of the CBD itself most benefit sharing provisions are non-binding. All other key instruments presented here – the Declaration of Helsinki, the CIOMS International Ethical Guidelines for Biomedical Research Involving Human Subjects, the HUGO Ethics Committee’s Statement on Benefit Sharing, and UNESCO’s Universal Declaration on the Human Genome and Human Rights, and Universal Declaration on Bioethics and Human Rights – are non-binding. Yet even when the law is clear and binding, compliance is not usually easily achieved. The access and benefit-sharing provisions of the CBD have been incorporated into national law in many countries world-wide, but success stories are still hard to find. It is hoped that the 2010 Nagoya Protocol to the CBD will address this shortfall for non-human biological resources. An example from Brazilian national legislation, which is discussed here, is encouraging in terms of achieving benefit sharing with those providing access to human biological resources. However at the global level, benefit sharing for human biological resources remains an unresolved and often contentious issue.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    This revision and the Clinton administration’s role in imposing it are discussed in Pogge (2008: 131–132).

  2. 2.

    http://www.cbd.int/convention/parties/list/

  3. 3.

    ‘The Conference of the Parties … [r]eaffirms that human genetic resources are not included within the framework of the Convention’ (CBD COP Decision II/11, paragraph 2, http://www.cbd.int/decision/cop/?id=7084).

  4. 4.

    United States (IP/C/W/434). See also proposals from Australia, (IP/C/W/310) and Japan (IP/C/W/236). (Sources referred to in these notes with numbers commencing ‘IP/C’ are working documents of the Council for TRIPS.)

  5. 5.

    African Group (IP/C/W/404); Kenya (IP/C/M/47); Brazil, India, Pakistan, Peru, Thailand and Venezuela (IP/C/W/429/Rev.1); India(IP/C/W/198).

  6. 6.

    Australia(IP/C/M/48); Canada(IP/C/M/47); New Zealand (IP/C/M/47); Andean community (IP/C/M/37/Add.1, paragraph 231); Brazil(IP/C/W/228); China(IP/C/M/47, paragraph 57).

  7. 7.

    For the text of the decision adopting the protocol, see http://www.cbd.int/decision/cop/?id=12267.

  8. 8.

    Since the protocol’s adoption, a group of indigenous organizations has sent a submission to the executive secretary of the CBD secretariat outlining ‘substantive and procedural injustices’ (http://www.ubcic.bc.ca/files/PDF/NagoyaProtocol_IGCJointSubmission_060111.pdf) – for instance, the fact that ‘excessive reliance on national legislation is likely to lead to serious abuses, in light of the history of violations’ and the lack of ‘full and effective participation’ by indigenous representatives during the negotiations.

  9. 9.

    This development, the mentioning of human pathogens in the Nagoya Protocol, marks a departure from the approach otherwise taken in CBD legislation, which since 1995 excludes material of human origin.

  10. 10.

    It should be noted that prior to the Second World War, no international ethical standards existed to regulate research on human subjects. National standards were also scarce. For a detailed look at the history and development of the Declaration of Helsinki see Human and Fluss (2001).

  11. 11.

    See Andanda (2006: 60–61) for a detailed discussion of this regime.

  12. 12.

    http://www.wma.net/en/60about/10members/20memberlist/index.html

  13. 13.

    We agree with Udo Schuklenk on this claim. When comparing the Declaration of Helsinki with other influential guidelines, Schuklenk argues that ‘an international consensus among smallish operators with impressive names is not a sufficient reason to do away with the authority of the WMA, which represents more members of the medical profession in one single country, let alone across the world, than the rest of the organisations and institutions mentioned … combined’. See Schuklenk (2004: 196).

  14. 14.

    Interview with a member of the Kenya Medical Research Institute (KEMRI) Ethical Review Committee quoted in Andanda and Cook Lucas (2007).

  15. 15.

    For a detailed discussion of these two concepts of justice in the context of benefit sharing, see Schroeder and Pogge (2009: 274).

  16. 16.

    See a further explanation of the two notions in part 3.6 of this chapter, particularly where article 12(a) of UNESCO’s Universal Declaration on the Human Genome and Human Rights (UNESCO 1997) is discussed.

  17. 17.

    For a detailed analysis of the concept of solidarity in the context of benefit sharing see Simm (2006).

  18. 18.

    Thanks to Bruno Schlemper Junior for providing an up-date on Brazilian national legislation to DS.

References

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pamela Andanda .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Andanda, P., Schroeder, D., Chaturvedi, S., Mengesha, E., Hodges, T. (2013). Legal Frameworks for Benefit Sharing: From Biodiversity to Human Genomics. In: Schroeder, D., Cook Lucas, J. (eds) Benefit Sharing. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6205-3_3

Download citation

Publish with us

Policies and ethics